Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
Those with significant medical co-morbidities, prior CSF diversion procedures, neurovascular stenting or optic nerve sheath fenestration, those currently using GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or taking drugs that could reduce ICP were excluded
Some patients approach GLP-1 therapy as a temporary intervention, aiming to achieve a target weight before discontinuing treatment
Our Law Firm Can Handle YourOzempic Weight Loss Drug Stomach Paralysis Lawsuit Have you or a loved one taken a GLP-1 RA like Ozempic and been diagnosed with gastroparesis (stomach paralysis) or gastric obstruction
Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H